Complete Response With Trametinib in Advanced Low-Grade Serous Ovarian Carcinoma: A Case Report

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Low-grade serous ovarian carcinoma (LGSOC) presents unique challenges due to chemoresistance and poor prognosis.
• Standard treatment often involves platinum-based chemotherapy and cytoreduction, but recurrence is common.

Observation:

• A 45-year-old female with stage III-C LGSOC experienced relapse after initial chemotherapy and cytoreduction.
• Hormonal therapy was ineffective, and chemotherapy was refused; bevacizumab provided 30 months of stabilization.

Findings:

• Single-agent trametinib, a MEK inhibitor, induced a sustained complete response for over 36 months in recurrent LGSOC.
• This represents the first reported complete response to a MEK inhibitor outside clinical trials for recurrent LGSOC with unknown BRAF V600E mutation.

Implications:

• Trametinib may offer a novel therapeutic option for patients with advanced or recurrent LGSOC, particularly those refractory to other treatments.
• Further investigation into MEK inhibitor efficacy in LGSOC, irrespective of BRAF mutation status, is warranted.